PMID- 34659430
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - LncRNA-URHC Functions as ceRNA to Regulate DNAJB9 Expression by Competitively 
      Binding to miR-5007-3p in Hepatocellular Carcinoma.
PG  - 3031482
LID - 10.1155/2021/3031482 [doi]
LID - 3031482
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is often diagnosed at a late stage, 
      when the prognosis is poor. The regulation of long noncoding RNAs (lncRNAs) plays 
      a crucial role in HCC. However, the precise regulatory mechanisms of lncRNA 
      signaling in HCC remain largely unknown. Our study aims to investigate the 
      underlying mechanisms of lncRNA (upregulated in hepatocellular carcinoma) URHC in 
      HCC. OBJECTIVE: To study the in vivo and in vitro localization and biological 
      effects of URHC on liver cancer cells. Through bioinformatics analysis, 
      dual-luciferase reporter gene analysis and rescue experiments revealed the 
      possible mechanism of URHC. METHODS: RT-qPCR, fluorescence in situ hybridization 
      (FISH) staining, EdU, colony formation, and tumor xenograft experiments were used 
      to identify localized and biological effects of URHC on HCC cells in vitro and in 
      vivo. The bioinformatics analysis, dual-luciferase reporter assay, and rescue 
      experiments revealed the potential mechanism of URHC. RESULTS: URHC silencing may 
      inhibit the HCC cells' proliferation in vitro and in vivo. We found that URHC was 
      mainly localized in the cytoplasm. The expression of miR-5007-3p was negatively 
      regulated by URHC. And miR-5007-3p could reverse the effect of URHC in HCC cells. 
      The expression of DNAJB9 was negatively regulated by miR-5007-3p but positively 
      regulated by URHC. These suggestive of lncRNA-URHC positively regulated the level 
      of DNAJB9 by sponging miR-5007-3p. CONCLUSION: Together, our study elucidated the 
      role of URHC as a miRNA sponge in HCC and shed new light on lncRNA-directed 
      diagnostics and therapeutics in HCC.
CI  - Copyright (c) 2021 Kunwei Niu et al.
FAU - Niu, Kunwei
AU  - Niu K
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Qu, Shibin
AU  - Qu S
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Zhang, Xuan
AU  - Zhang X
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Dai, Jimin
AU  - Dai J
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Wang, Jianlin
AU  - Wang J
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Nie, Ye
AU  - Nie Y
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Tao, Kaishan
AU  - Tao K
AUID- ORCID: 0000-0002-8573-0445
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
FAU - Song, Wenjie
AU  - Song W
AUID- ORCID: 0000-0002-6628-7302
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical 
      University, 127 Changle Road, Xi'an, Shaanxi 710032, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20211007
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Jun 21;2023:9789637. PMID: 37387927
PMC - PMC8516585
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/10/19 06:00
MHDA- 2021/10/19 06:01
PMCR- 2021/10/07
CRDT- 2021/10/18 08:57
PHST- 2021/08/24 00:00 [received]
PHST- 2021/09/14 00:00 [accepted]
PHST- 2021/10/18 08:57 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2021/10/19 06:01 [medline]
PHST- 2021/10/07 00:00 [pmc-release]
AID - 10.1155/2021/3031482 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Oct 7;2021:3031482. doi: 
      10.1155/2021/3031482. eCollection 2021.